Ajit Singh Appointed CEO of Harbinger Health and CEO-Partner of Flagship Pioneering
Leadership Transition at Harbinger Health: Ajit Singh, Ph.D., has been appointed as the new CEO of Harbinger Health, succeeding Stephen Hahn, M.D., who will transition to CEO Emeritus and Special Advisor while remaining on the board. Dr. Singh brings extensive experience in diagnostics, particularly in oncology.
Innovative Cancer Detection Approach: Harbinger Health is focused on developing blood-based tests for early cancer detection using proprietary methylation patterns and advanced AI technologies, aiming to transform cancer screening and diagnosis into routine health practices.
Trade with 70% Backtested Accuracy
Analyst Views on FHTX
About FHTX
About the author
GT Biopharma Advances GTB-3650 Clinical Trial to Cohort 4
- Clinical Progress: GT Biopharma's GTB-3650 has advanced to Cohort 4 in its clinical trial at a dose of 10 µg/kg/day, demonstrating good tolerability and potential efficacy, which is expected to provide new treatment options for patients with refractory blood cancers.
- Market Potential: The U.S. oncology market is projected to surge from $81 billion in 2025 to $212 billion by 2034, with monoclonal antibodies and cell therapies leading this growth, positioning GT Biopharma within this rapidly expanding sector.
- Technological Advantage: GTB-3650 employs the company's proprietary TriKE platform technology to stimulate patients' natural killer cells to target cancer cells, showing promise in treating acute myeloid leukemia and high-risk myelodysplastic syndrome.
- Future Plans: The company plans to provide the next trial update in Q1 2026 and expects to submit a regulatory application for GTB-5550 by late December 2025 or January 2026, further expanding its therapeutic pipeline.
Foghorn Therapeutics Set to Attend Three Upcoming Investor Conferences
Company Overview: Foghorn Therapeutics Inc. is a clinical-stage biotechnology company focused on developing medicines that correct abnormal gene expression, particularly in oncology, through its Gene Traffic Control® platform.
Upcoming Conferences: The company will participate in three major healthcare conferences: Guggenheim Second Annual Healthcare Innovation Conference, Stifel 2025 Healthcare Conference, and Jefferies 2025 London Healthcare Conference, with presentations by CEO Adrian Gottschalk.
Presentation Details: Foghorn's management will engage in fireside chats and one-on-one meetings at these conferences, providing insights into their innovative approaches and pipeline.
Webcast Availability: Presentations from the conferences will be accessible via the company's website under "Events & Presentations" for 90 days following the events.
Flagship Pioneering Appoints Rahul Kakkar as CEO-Partner and CEO of Quotient Therapeutics
Leadership Changes: Dr. Rahul Kakkar has been appointed as CEO-Partner at Flagship Pioneering and CEO of Quotient Therapeutics, bringing nearly 20 years of experience in biotechnology and medicine, including previous leadership roles at Tome Biosciences and Pandion Therapeutics.
Quotient's Mission: Quotient Therapeutics aims to leverage its Somatic Genomics platform to discover novel drug targets and develop transformative medicines that address a wide range of diseases, with Dr. Kakkar expressing enthusiasm for advancing the company's pipeline and technology.
JMP Securities Initiates Coverage On Foghorn Therapeutics with Market Outperform Rating, Announces Price Target of $9
Real-time Intelligence: Benzinga Pro offers the fastest news alerts and real-time intelligence for traders to enhance their market performance.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from exclusive stories and accurate stock market insights.
HC Wainwright & Co. Reiterates Buy on Foghorn Therapeutics, Lowers Price Target to $13
Fastest News Alerts: Benzinga Pro offers real-time intelligence and alerts to help traders stay informed and make winning trades in the stock market.
Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and accurate market intelligence.
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
Foghorn Therapeutics Conference Participation: Foghorn Therapeutics Inc. will participate in multiple healthcare conferences, including the Jefferies London Healthcare Conference, Evercore HealthCONx Conference, and Citi Global Healthcare Conference, with CEO Adrian Gottschalk presenting at fireside chats and engaging in one-on-one meetings.
Innovative Gene Therapy Approach: The company is focused on developing a new class of medicines using its Gene Traffic Control® platform to target genetically determined dependencies within the chromatin regulatory system, primarily aimed at oncology treatments.
GT Biopharma Advances GTB-3650 Clinical Trial to Cohort 4
- Clinical Progress: GT Biopharma's GTB-3650 has advanced to Cohort 4 in its clinical trial at a dose of 10 µg/kg/day, demonstrating good tolerability and potential efficacy, which is expected to provide new treatment options for patients with refractory blood cancers.
- Market Potential: The U.S. oncology market is projected to surge from $81 billion in 2025 to $212 billion by 2034, with monoclonal antibodies and cell therapies leading this growth, positioning GT Biopharma within this rapidly expanding sector.
- Technological Advantage: GTB-3650 employs the company's proprietary TriKE platform technology to stimulate patients' natural killer cells to target cancer cells, showing promise in treating acute myeloid leukemia and high-risk myelodysplastic syndrome.
- Future Plans: The company plans to provide the next trial update in Q1 2026 and expects to submit a regulatory application for GTB-5550 by late December 2025 or January 2026, further expanding its therapeutic pipeline.
Foghorn Therapeutics Set to Attend Three Upcoming Investor Conferences
Company Overview: Foghorn Therapeutics Inc. is a clinical-stage biotechnology company focused on developing medicines that correct abnormal gene expression, particularly in oncology, through its Gene Traffic Control® platform.
Upcoming Conferences: The company will participate in three major healthcare conferences: Guggenheim Second Annual Healthcare Innovation Conference, Stifel 2025 Healthcare Conference, and Jefferies 2025 London Healthcare Conference, with presentations by CEO Adrian Gottschalk.
Presentation Details: Foghorn's management will engage in fireside chats and one-on-one meetings at these conferences, providing insights into their innovative approaches and pipeline.
Webcast Availability: Presentations from the conferences will be accessible via the company's website under "Events & Presentations" for 90 days following the events.
Flagship Pioneering Appoints Rahul Kakkar as CEO-Partner and CEO of Quotient Therapeutics
Leadership Changes: Dr. Rahul Kakkar has been appointed as CEO-Partner at Flagship Pioneering and CEO of Quotient Therapeutics, bringing nearly 20 years of experience in biotechnology and medicine, including previous leadership roles at Tome Biosciences and Pandion Therapeutics.
Quotient's Mission: Quotient Therapeutics aims to leverage its Somatic Genomics platform to discover novel drug targets and develop transformative medicines that address a wide range of diseases, with Dr. Kakkar expressing enthusiasm for advancing the company's pipeline and technology.
JMP Securities Initiates Coverage On Foghorn Therapeutics with Market Outperform Rating, Announces Price Target of $9
Real-time Intelligence: Benzinga Pro offers the fastest news alerts and real-time intelligence for traders to enhance their market performance.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from exclusive stories and accurate stock market insights.
HC Wainwright & Co. Reiterates Buy on Foghorn Therapeutics, Lowers Price Target to $13
Fastest News Alerts: Benzinga Pro offers real-time intelligence and alerts to help traders stay informed and make winning trades in the stock market.
Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and accurate market intelligence.
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
Foghorn Therapeutics Conference Participation: Foghorn Therapeutics Inc. will participate in multiple healthcare conferences, including the Jefferies London Healthcare Conference, Evercore HealthCONx Conference, and Citi Global Healthcare Conference, with CEO Adrian Gottschalk presenting at fireside chats and engaging in one-on-one meetings.
Innovative Gene Therapy Approach: The company is focused on developing a new class of medicines using its Gene Traffic Control® platform to target genetically determined dependencies within the chromatin regulatory system, primarily aimed at oncology treatments.
